VE
Venus Remedies Ltd (VENUSREM)
₹1,502.00
Mkt cap
₹2,002 Cr
P/E ratio
16.40
P/B
2.85
Div yield
0.67%
ROE
15.60%
ROCE
20.70%
EPS (TTM)
₹91.59
Book value
₹527
52W range
550–2,044
Sector
Healthcare
Price history
Previous close
Incorporated in 1989, Venus Remedies Ltd is a research-based pharmaceutical company focused on complex injectable formulations across critical care, oncology, anti-infectives and specialty therapies. It operates across 100+ countries, with a product basket of 195+, 1,100+ marketing authorisations and 700+ dossiers filed.{# {# https://www.bseindia.com/xml-data/corpfiling/AttachHis/29971821-bfab-4659-a9d8-7cf5dc170d02.pdf#page=36 #} #}
NSE VENUSREMBSE 526953
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−26.53% from high₹1,502
₹550+173.09% from low₹2,044
Current
₹1,502.00
Prev close
₹1,513.00
Day
−0.73%
Price performance
1D
−0.73%
1W
+0.28%
1M
+4.20%
3M
−14.93%
6M
+45.75%
1Y
+162.66%
YTD
+92.66%
Financials
Revenue, profit & margin
P/E ratio
16.4×
VENUSREM is 52% below the sector median of 34.0×
VENUSREM16.4×
Sector median34.0×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 168 | 143 | 195 | 109 | 170 | 177 | 195 | 137 | 193 | 180 | 259 | 179 | 219 | |
| YoY Sales growth | +20% | +23% | +25% | +14% | +1% | +23% | -0% | +26% | +13% | +2% | +33% | +30% | +13% | |
| Expenses | 150 | 131 | 176 | 97 | 163 | 158 | 166 | 122 | 162 | 143 | 196 | 145 | 176 | |
| Operating Profit | 18 | 12 | 19 | 11 | 8 | 18 | 29 | 15 | 31 | 38 | 63 | 34 | 42 | |
| OPM % | 11% | 8% | 10% | 10% | 4.5% | 10% | 15% | 11% | 16% | 21% | 24% | 19% | 19% | |
| Other Income | 3 | 2 | 4 | 2 | 8 | 12 | 7 | 3 | 2 | 3 | 5 | 3 | 1 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 6 | 7 | 6 | 6 | 6 | 5 | 5 | 6 | 6 | 7 | 7 | 7 | 10 | |
| Profit before tax | 14 | 8 | 17 | 7 | 9 | 25 | 31 | 13 | 26 | 33 | 62 | 30 | 33 | |
| Tax % | 31% | 12% | 40% | 82% | 61% | 21% | 32% | 24% | 24% | 24% | 23% | 24% | 23% | |
| Net Profit | 10 | 7 | 11 | 1 | 4 | 20 | 21 | 10 | 20 | 26 | 48 | 23 | 26 | |
| EPS in Rs | 7.44 | 5.12 | 7.86 | 0.91 | 2.63 | 14.66 | 15.71 | 7.18 | 15.06 | 19.14 | 35.54 | 17.18 | 19.19 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −4.99% · closed higher next day 0 of last 1
| Q2FY27 | |
|---|---|
| Broadcast | 26 Oct '26◦ |
| Earnings day | −4.99% |
| +1 day | −9.00% |
| +5 days | −10.03% |
| +15 days | −0.47% |
| +30 days | — |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Sep 202641.76%Promoter
Promoters41.76%
FIIs3.14%0.22
DIIs0.74%0.15
Public54.37%0.07
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,880.00 | 36.66 | 4,51,075 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,442.00 | 88.89 | 3,03,749 | 0.26% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,670.00 | 81.82 | 1,77,632 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,424.00 | 97.75 | 1,30,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,189.90 | 26.20 | 1,18,693 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,380.00 | 41.17 | 1,15,267 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,391.80 | 36.21 | 1,12,442 | 0.93% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Venus Remedies | ₹1,497.80 | 16.45 | 2,002 | 0.67% | 26 | +27.42% | 219 | +13.49% | 20.71% |
| Median: 160 Co. | ₹465.83 | 33.99 | 2,012 | 0.08% | 13 | +33.53% | 179 | +20.92% | 14.94% |
Filings
Annual reports15
Credit ratings4
Announcements5
Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares Of Venus Remedies Limited 5 Nov - Shared social media links for special window to re-lodge physical share transfer requests.Announcement under Regulation 30 (LODR)-Newspaper Publication 4 NovAnnouncement under Regulation 30 (LODR)-Newspaper Publication 28 OctUnaudited Financial Results For The Period Ended On 30Th September 2026. 26 OctBoard Meeting Outcome for Outcome Of Board Meeting Date 26Th October 2026 And Unaudited Financial Results For The Period Ended On 30Th September 2026. 26 Oct - Board approved unaudited standalone and consolidated Q2 FY2026-27 results on 26 Oct 2026.






